ALC · Alcon Inc
$74.25
+0.73 (+0.99%)
At close · Aug 14
Market Cap
$35.97B
Shares
483.40M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$74.25
Open$74.33
Day$74.02–74.92
52W close$62.02–90.12
Avg vol 30d2.3M
Short int13.7M · 2.8% float · 6.1d
Short vol74%
Last earningsNov 11, 2026
DataJan 2020–Aug 2026
Up next
Next earnings call
Nov 11, 2026
Scheduled
· in 13 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Bearish
Fundamentals
Excellent
Quant / Vol
Moderate
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−1%
below
Price vs 50-day avg
+8%
above
RSI (14)
64
neutral
MACD trend
Positive
52-week position
44%
mid-range
Momentum
relative strength
1-month return
+6%
trailing
6-month return
−10%
trailing
YTD return
−6%
this year
Relative strength
−24%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $68 › 200d $75 — 200d above 50d
Institutional flow
Distributing
-6% holders QoQ · +79 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.83% of float · ▲ +5.0% MoM · 6.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
620 holders — near 3-yr low, contrarian setup
Squeeze score
59
elevated · 0–100
Fundamentals
Revenue growth
+10%
Y/Y
Gross margin
77%
expanding
EPS growth
+9%
Y/Y
Free cash flow
$2.1B
Buyback
$750.0M
authorized
Balance sheet
$2.5B
net cash
Quant / Vol
risk profile
Volatility
30%
annualized · 1-yr
Max drawdown
−31%
past year
ATR
2.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Sep 30, 2025
Sales
· full year
$10.3B – $10.4B
Constant currency growth
· full year
4% – 5%
Core operating margin
· full year
Non-GAAP
19.5% – 20.5%
R&D as a percent of sales
· full year
8% – 10%
Nonoperating expense
· full year
$185M – $205M
Prior guidance
period ended
· from the Earnings Call filed Mar 31, 2024
Top-line guidance
· full-year 2024
$9.9B – $10.1B
Constant currency sales growth
· full-year 2024
7% – 9%
Core operating margin
· full-year 2024
20.5% – 21.5%
Core diluted earnings
· full-year 2024
$3.00 – $3.10
Interest and other financial expenses
· full-year 2024
$180M – $200M
Top-line
· full year 2024
$9.9B – $10.1B
Constant currency sales growth
· full year 2024
7% – 9%
Core R&D expense
· full year 2024
7% – 9%
Core effective tax rate
· full year 2024
20%
Constant currency growth in core diluted earnings
· full year 2024
15% – 18%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−1%
Neutral
Price vs 50-day avg
+8%
Bullish
RSI (14)
64
Neutral
MACD trend
Positive
Bullish
52-week position
44%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $68 › 200d $75 — 200d above 50d
Institutional flow
Distributing
-6% holders QoQ · +79 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.83% of float · ▲ +5.0% MoM · 6.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
620 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $62
Now $74 · 44%
Range high $90
vs 200-day avg -1%
vs 50-day avg +8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALC
this stock
Alcon Inc
|
$35.97B | -5.8% | +10.5% | — | 2.8% |
|
ISRG
Intuitive Surgical Inc
|
$139.37B | -30.3% | +20.5% | 45.3 | 1.9% |
|
BDX
Becton Dickinson & Co
|
$49.96B | — | +8.2% | — | 3.7% |
|
MDLN
Medline Inc.
|
$46.99B | -14.9% | +11.5% | — | 2.6% |
|
RMD
Resmed Inc
|
$32.38B | -6.8% | +13.4% | 21.5 | 10.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALC | +3.4% | +5.7% | -10.4% | +7.7% | -5.8% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +3.0% | +1.2% | -24.2% | +3.8% | -19.6% |
Capital returns
Latest dividend
$0.358
/ share · ex May 5, 2026
Paid (TTM)
$0.358
/ share · 1 payout
Dividend yield (TTM, derived)
— · history filling in
Buyback program
· as of Feb 25, 2025
Authorized
$750.00M
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1167379
CUSIP
H01301128
13F (30d)
600 filings
574 filers
Visit website
Investor relations